|Bid||13.43 x 1100|
|Ask||13.45 x 800|
|Day's Range||13.26 - 13.58|
|52 Week Range||9.55 - 32.20|
|Beta (3Y Monthly)||2.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.75|
Momenta Pharmaceuticals Inc NASDAQ/NGS:MNTAView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for MNTA with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MNTA had net inflows of $2.70 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced new preclinical data for M281, its potentially best-in-class anti-FcRn antibody, was published in the American Journal of Obstetrics & Gynecology.
In 2006 Craig Wheeler was appointed CEO of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'llRead More...
Momenta (MNTA) delivered earnings and revenue surprises of 84.78% and 102.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 10 cents. Losses, adjusted for restructuring costs, were 7 cents per share. The results topped Wall Street expectations. ...
-- Ended 2018 with a cash position of $449.0 million -- -- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN).
Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Management will host a conference call on February 22, 2019 at 8:30 a.m. ET to discuss these results and provide an update on the company. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases.
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the selection of new research for its product candidate, M281, for an oral presentation at the Society for Maternal-Fetal Medicine (SMFM)'s 39th Annual Pregnancy Meeting. “We believe M281 has the ability to be a first-in-class therapy for women carrying a fetus who are at high risk of suffering from early onset severe HDFN.
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the dosing of the first subject in the Phase 1/2 clinical trial of M254, hypersialylated Immunoglobulin G (hsIgG). The Phase 1/2 study will enroll normal healthy volunteers and patients with Immune Thrombocytopenic Purpura (ITP). The multi-part study includes single and multiple dose parts, and a placebo-controlled, randomized double-blinded cross-over study comparing M254 to IVIg.
NEW YORK, Jan. 23, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The direct benefit for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
CAMBRIDGE, Mass., Jan. 02, 2019 -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler, President and CEO, will present at the 37th Annual J.P..
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Is Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) a […]
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced the closing of its underwritten public offering of 20,000,000 shares of its common stock at the public offering price of $11.50 per share, which includes the exercise in full of the underwriter’s option to purchase additional shares of common stock. The final prospectus supplement has been filed with the SEC and forms a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or e-mail at email@example.com.
Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.